AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 33076714 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon (IFN)
Number of subjects: 0
Study 33076714 — intervention group
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Number of subjects: 0
Study 33076714 — intervention group
Group type: COMPARATOR
Intervention: Hydroxyurea
Number of subjects: 0
Study 34974277 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinesio Taping (KT) plus Oral-Motor Training (OMT)
Number of subjects: 18
Study 34974277 — intervention group
Group type: COMPARATOR
Intervention: Sham Taping plus Oral-Motor Training (OMT)
Number of subjects: 18
Study 34974277 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (KT + OMT and Sham Taping + OMT)
Number of subjects: 18
Study 34452940 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquefied petroleum gas (LPG) cookstoves
Number of subjects: 1414
Study 34452940 — intervention group
Group type: EXPERIMENTAL
Intervention: Improved biomass cookstoves
Number of subjects: 1414
Study 34452940 — intervention group
Group type: COMPARATOR
Intervention: Control group (traditional stoves)
Number of subjects: 1414
Study 33151187 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic navigation using trace registration (TR) technology
Number of subjects: 39
Study 33151187 — intervention group
Group type: COMPARATOR
Intervention: Free-hand surgery
Number of subjects: 39
Study 33151187 — intervention group
Group type: EXPERIMENTAL
Intervention: Both TR and free-hand implants
Number of subjects: 39
Study 33640979 — intervention group
Group type: EXPERIMENTAL
Intervention: Tele-Savvy (active arm)
Number of subjects: 261
Study 33640979 — intervention group
Group type: COMPARATOR
Intervention: Attention control
Number of subjects: 261
Study 33640979 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 261
Study 33964394 — intervention group
Group type: EXPERIMENTAL
Intervention: Live observational scoring
Number of subjects: 18
Study 33964394 — intervention group
Group type: COMPARATOR
Intervention: Delayed video review
Number of subjects: 18
Study 34341306 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrin Sealant
Number of subjects: 40
Study 34341306 — intervention group
Group type: COMPARATOR
Intervention: Hypospadias Repair (Control)
Number of subjects: 40
Study 35412965 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional hypnotherapy
Number of subjects: 144
Study 35412965 — intervention group
Group type: EXPERIMENTAL
Intervention: Ericksonian hypnotherapy
Number of subjects: 144
Study 35412965 — intervention group
Group type: COMPARATOR
Intervention: Educational talk
Number of subjects: 144
Study 33513226 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplementation (2000 IU/day)
Number of subjects: 771
Study 33513226 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 771
Study 36513465 — intervention group
Group type: EXPERIMENTAL
Intervention: Synbiotic plus vitamin D
Number of subjects: 88
Study 36513465 — intervention group
Group type: EXPERIMENTAL
Intervention: Synbiotic
Number of subjects: 88
Study 36513465 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D
Number of subjects: 88
Study 36513465 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88
Study 33762428 — intervention group
Group type: EXPERIMENTAL
Intervention: Epigallocatechin‐3‐gallate (EGCG) 800 mg daily for 18 months
Number of subjects: 122
Study 33762428 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 122
Study 34951974 — intervention group
Group type: EXPERIMENTAL
Intervention: DSJI (Disposable Syringe Jet Injector)
Number of subjects: 2720
Study 34951974 — intervention group
Group type: COMPARATOR
Intervention: N&S (Needle and Syringe)
Number of subjects: 2720
Study 34951974 — intervention group
Group type: EXPERIMENTAL
Intervention: IDA (Intradermal Adaptor)
Number of subjects: 2720
Study 34951974 — intervention group
Group type: EXPERIMENTAL
Intervention: IDA
Number of subjects: 2720
Study 34951974 — intervention group
Group type: EXPERIMENTAL
Intervention: DSJI
Number of subjects: 2720
Study 34951974 — intervention group
Group type: EXPERIMENTAL
Intervention: IDA and DSJI
Number of subjects: 2720
Study 34951974 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 2720
Study 33810796 — intervention group
Group type: EXPERIMENTAL
Intervention: KB109 in addition to supportive self-care (SSC)
Number of subjects: 400
Study 33810796 — intervention group
Group type: EXPERIMENTAL
Intervention: KB109 in addition to SSC
Number of subjects: 400
Study 33810796 — intervention group
Group type: COMPARATOR
Intervention: SSC alone
Number of subjects: 400
Study 33069301 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytisine (9 mg on day 0, gradually reduced to 1.5 mg by day 25)
Number of subjects: 2472
Study 33069301 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2472
Study 33069301 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytisine
Number of subjects: 2472
Study 36195897 — intervention group
Group type: EXPERIMENTAL
Intervention: Social norm feedback on antibiotic prescribing
Number of subjects: 2000
Study 36195897 — intervention group
Group type: EXPERIMENTAL
Intervention: Social norm feedback plus online training on rational prescribing practice and communication strategies
Number of subjects: 2000
Study 36195897 — intervention group
Group type: EXPERIMENTAL
Intervention: Social norm feedback plus online peer-moderated training on rational antibiotic prescribing, communication strategies, and sustainable behavior change
Number of subjects: 2000
Study 36195897 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 2000
Study 34830709 — intervention group
Group type: EXPERIMENTAL
Intervention: Internal conical connection implants
Number of subjects: 30
Study 34830709 — intervention group
Group type: COMPARATOR
Intervention: Internal hexagonal connection implants
Number of subjects: 30
Study 35426033 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine 60 mg capsule for 14 days during each chemotherapy cycle
Number of subjects: 32
Study 35426033 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 14 days during each chemotherapy cycle
Number of subjects: 32
Study 33651748 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose omega-3 fatty acids
Number of subjects: 0
Study 33651748 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose colchicine
Number of subjects: 0
Study 32828167 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-delivered psychosocial intervention
Number of subjects: 1154
Study 32828167 — intervention group
Group type: COMPARATOR
Intervention: Enhanced usual care
Number of subjects: 1154
Study 34258637 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D fat-saturated-CAIPIRINHA SPACE MRI
Number of subjects: 49
Study 34258637 — intervention group
Group type: COMPARATOR
Intervention: 2D TSE MRI
Number of subjects: 49
Study 33250314 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg/day Oligopin®
Number of subjects: 43
Study 33250314 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study 35936217 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetyl-L-Carnitine (ALC) 1000 mg three times per day for three consecutive days
Number of subjects: 69
Study 35936217 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study 35445808 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined CPAP and tolterodine treatment
Number of subjects: 60
Study 35445808 — intervention group
Group type: COMPARATOR
Intervention: CPAP treatment only
Number of subjects: 60
Study 34213794 — intervention group
Group type: EXPERIMENTAL
Intervention: VR immersion (experimental group, n = 20)
Number of subjects: 40
Study 34213794 — intervention group
Group type: COMPARATOR
Intervention: Audio immersion (control group, n = 20)
Number of subjects: 40
Study 34192396 — intervention group
Group type: EXPERIMENTAL
Intervention: Limosilactobacillus reuteri DSM‐17938
Number of subjects: 17
Study 34192396 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 32775414 — intervention group
Group type: EXPERIMENTAL
Intervention: Random practice
Number of subjects: 21
Study 32775414 — intervention group
Group type: EXPERIMENTAL
Intervention: Constant practice
Number of subjects: 21
Study 32775414 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy individuals)
Number of subjects: 21
Study 36240174 — intervention group
Group type: EXPERIMENTAL
Intervention: PINCER intervention
Number of subjects: 46
Study 34051544 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate reduction from 15.5 to 0.4 mg of nicotine per gram of tobacco (mg/g)
Number of subjects: 1250
Study 34051544 — intervention group
Group type: EXPERIMENTAL
Intervention: Gradual reduction to 0.4 mg/g
Number of subjects: 1250
Study 34051544 — intervention group
Group type: COMPARATOR
Intervention: Control group with normal nicotine cigarettes (15.5 mg/g)
Number of subjects: 1250
Study 33378308 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular revascularization plus supervised exercise
Number of subjects: 212
Study 33378308 — intervention group
Group type: COMPARATOR
Intervention: Supervised exercise only
Number of subjects: 212
Study 34328109 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic supplementation (500 mg capsule containing Lactobacillus acidophilus LA1, Bifidobacterium longum sp54 cs, and Bifidobacterium bifidum sp9 cs)
Number of subjects: 507
Study 34328109 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 507
Study 36345556 — intervention group
Group type: EXPERIMENTAL
Intervention: Global Deficit Score (GDS) from neuropsychological measures
Number of subjects: 119
Study 36345556 — intervention group
Group type: EXPERIMENTAL
Intervention: PTSD symptom severity assessed using the PTSD Checklist‐Military Version
Number of subjects: 119
Study 36345556 — intervention group
Group type: EXPERIMENTAL
Intervention: Performance in the verbal learning and memory domain
Number of subjects: 119
Study 36345556 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple linear regressions with GDS and PTSD symptom severity
Number of subjects: 119
Study 32214139 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural bolus (0.15% ropivacaine 0.3 ml·kg‐1)
Number of subjects: 40
Study 32214139 — intervention group
Group type: COMPARATOR
Intervention: Continuous epidural infusion (0.15% ropivacaine 0.3 ml·kg‐1)
Number of subjects: 40
Study 34212185 — intervention group
Group type: EXPERIMENTAL
Intervention: Rehabilitation Gaming System (RGS)
Number of subjects: 20
Study 33661714 — intervention group
Group type: EXPERIMENTAL
Intervention: Oat flour and pea protein (protein)
Number of subjects: 26
Study 33661714 — intervention group
Group type: EXPERIMENTAL
Intervention: Oat flour, pea starch and pea protein (starch+protein)
Number of subjects: 26
Study 33661714 — intervention group
Group type: EXPERIMENTAL
Intervention: Oat flour, pea fibre and pea protein (fibre+protein)
Number of subjects: 26
Study 33661714 — intervention group
Group type: EXPERIMENTAL
Intervention: Oat flour, pea starch and pea protein (fibre+starch+protein)
Number of subjects: 26
Study 33661714 — intervention group
Group type: COMPARATOR
Intervention: Oat flour (control)
Number of subjects: 26
Study 33661714 — intervention group
Group type: COMPARATOR
Intervention: Oat flour and pea starch (starch)
Number of subjects: 26
Study 32070793 — intervention group
Group type: EXPERIMENTAL
Intervention: Early Manual Therapy Group (EMTG)
Number of subjects: 39
Study 32070793 — intervention group
Group type: COMPARATOR
Intervention: Standard Physiotherapy Group (SPG)
Number of subjects: 39
Study 35489646 — intervention group
Group type: EXPERIMENTAL
Intervention: HomeStyles‐2 nutrition education program
Number of subjects: 0
Study 35489646 — intervention group
Group type: COMPARATOR
Intervention: Attention control program
Number of subjects: 0
Study 33283421 — intervention group
Group type: EXPERIMENTAL
Intervention: HCH nursing care
Number of subjects: 60
Study 33283421 — intervention group
Group type: COMPARATOR
Intervention: Control (traditional nursing care)
Number of subjects: 60
Study 36343423 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosemary capsules, 1 capsule twice a day for 8 weeks
Number of subjects: 0
Study 36343423 — intervention group
Group type: COMPARATOR
Intervention: Placebo, 1 capsule twice a day for 8 weeks
Number of subjects: 0
Study 33066761 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyridostigmine bromide 60 mg/day P.O.
Number of subjects: 0
Study 33066761 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 34791423 — intervention group
Group type: EXPERIMENTAL
Intervention: SRC+CIH
Number of subjects: 210
Study 34791423 — intervention group
Group type: COMPARATOR
Intervention: SRC
Number of subjects: 210
Study 33945928 — intervention group
Group type: EXPERIMENTAL
Intervention: Sense of social connectedness and information source (newspapers, TV, word of mouth)
Number of subjects: 1300
Study 35039300 — intervention group
Group type: EXPERIMENTAL
Intervention: LEGO-based therapy
Number of subjects: 248
Study 35039300 — intervention group
Group type: COMPARATOR
Intervention: Usual support
Number of subjects: 248
Study 32030940 — intervention group
Group type: EXPERIMENTAL
Intervention: sacubitril/valsartan (Entresto®)
Number of subjects: 0
Study 32030940 — intervention group
Group type: COMPARATOR
Intervention: valsartan
Number of subjects: 0
Study 34521118 — intervention group
Group type: EXPERIMENTAL
Intervention: EndoRotor ablation
Number of subjects: 30
Study 34362303 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4 g/kg 10% IVIG administered every two weeks for five doses
Number of subjects: 50
Study 34362303 — intervention group
Group type: COMPARATOR
Intervention: 0.9% saline administered every two weeks for five doses (control)
Number of subjects: 50
Study 33004131 — intervention group
Group type: EXPERIMENTAL
Intervention: Canakinumab 50 mg
Number of subjects: 10061
Study 33004131 — intervention group
Group type: EXPERIMENTAL
Intervention: Canakinumab 150 mg
Number of subjects: 10061
Study 33004131 — intervention group
Group type: EXPERIMENTAL
Intervention: Canakinumab 300 mg
Number of subjects: 10061
Study 33004131 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10061
Study 35550645 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT-SAD)
Number of subjects: 160
Study 35550645 — intervention group
Group type: COMPARATOR
Intervention: Light therapy (LT)
Number of subjects: 160
Study 34018057 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine Learning (ML) using a random forest algorithm trained on 10 features extracted from ultrasound images.
Number of subjects: 201
Study 34018057 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine Learning (ML) aiding a breast radiologist.
Number of subjects: 201
Study 34018057 — intervention group
Group type: COMPARATOR
Intervention: Breast radiologist without ML assistance.
Number of subjects: 201
Study 34397282 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A (1 RME activation per day)
Number of subjects: 26
Study 34397282 — intervention group
Group type: COMPARATOR
Intervention: Group B (2 RME activations per day)
Number of subjects: 26
Study 33479844 — intervention group
Group type: COMPARATOR
Intervention: Bisphosphonates (BPs), predominantly alendronate, used by 9.4% of women and 1.5% of men.
Number of subjects: 28000
Study 33479844 — intervention group
Group type: COMPARATOR
Intervention: Glucocorticoids
Number of subjects: 28000
Study 35686864 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined ultrasound guided peritendinous hyaluronic acid (HA) injection with extracorporeal shock waves therapy (E‐g)
Number of subjects: 40
Study 35686864 — intervention group
Group type: COMPARATOR
Intervention: Extracorporeal shock waves therapy only (SC‐g)
Number of subjects: 40
Study 32472776 — intervention group
Group type: EXPERIMENTAL
Intervention: Fellow eye R
Number of subjects: 1960
Study 32472776 — intervention group
Group type: EXPERIMENTAL
Intervention: Regression formula from group A
Number of subjects: 1960
Study 32472776 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean R from group A
Number of subjects: 1960
Study 36175307 — intervention group
Group type: EXPERIMENTAL
Intervention: Enlarged lymph nodes in solid lesions
Number of subjects: 218
Study 36175307 — intervention group
Group type: EXPERIMENTAL
Intervention: Enlarged lymph nodes in subsolid lesions
Number of subjects: 218
Study 36175307 — intervention group
Group type: COMPARATOR
Intervention: Normal lymph nodes in control group
Number of subjects: 218
Study 34023151 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity (PA) participation
Number of subjects: 20806
Study 34023151 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported and accelerometer-based PA phenotypes
Number of subjects: 20806
Study 34394697 — intervention group
Group type: EXPERIMENTAL
Intervention: Richmond agitation and sedation scale
Number of subjects: 74
Study 33616478 — intervention group
Group type: EXPERIMENTAL
Intervention: HL02 (6 mg/kg)
Number of subjects: 107
Study 33616478 — intervention group
Group type: COMPARATOR
Intervention: US-trastuzumab
Number of subjects: 107
Study 33616478 — intervention group
Group type: EXPERIMENTAL
Intervention: HL02
Number of subjects: 107
Study 33616478 — intervention group
Group type: EXPERIMENTAL
Intervention: Both HL02 and US-trastuzumab
Number of subjects: 107
Study 33616478 — intervention group
Group type: EXPERIMENTAL
Intervention: HL02 and US-trastuzumab
Number of subjects: 107
Study 33140994 — intervention group
Group type: EXPERIMENTAL
Intervention: TAU plus a digital therapeutic (67 digital, interactive educational modules)
Number of subjects: 170
Study 33140994 — intervention group
Group type: COMPARATOR
Intervention: TAU (treatment-as-usual)
Number of subjects: 170
Study 33140994 — intervention group
Group type: EXPERIMENTAL
Intervention: TAU plus a digital therapeutic
Number of subjects: 170
Study 33140994 — intervention group
Group type: COMPARATOR
Intervention: TAU
Number of subjects: 170
Study 34730863 — intervention group
Group type: EXPERIMENTAL
Intervention: Real iTBS (intermittent theta burst stimulation)
Number of subjects: 22
Study 34730863 — intervention group
Group type: COMPARATOR
Intervention: Sham iTBS
Number of subjects: 22
Study 34730863 — intervention group
Group type: EXPERIMENTAL
Intervention: Real iTBS
Number of subjects: 22
Study 32640924 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to cyberterrorism
Number of subjects: 0
Study 36097996 — intervention group
Group type: EXPERIMENTAL
Intervention: Quarterly screening
Number of subjects: 8240
Study 36097996 — intervention group
Group type: COMPARATOR
Intervention: Annual screening
Number of subjects: 8240
Study 36097996 — intervention group
Group type: EXPERIMENTAL
Intervention: Quarterly screening plus
Number of subjects: 8240
Study 32541301 — intervention group
Group type: EXPERIMENTAL
Intervention: Tissue Anchoring System (TAS)
Number of subjects: 99
Study 32541301 — intervention group
Group type: COMPARATOR
Intervention: Traditional SSLF
Number of subjects: 99
Study 32422942 — intervention group
Group type: EXPERIMENTAL
Intervention: UDCA treatment (100 mg three times per day for two months)
Number of subjects: 24
Study 32422942 — intervention group
Group type: COMPARATOR
Intervention: Untreated group (monitored for two months without intervention)
Number of subjects: 24
Study 34919774 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT) based on playground games (MOVI-daFit!)
Number of subjects: 562
Study 33044102 — intervention group
Group type: EXPERIMENTAL
Intervention: Acarbose test formulation (T)
Number of subjects: 12
Study 33044102 — intervention group
Group type: COMPARATOR
Intervention: Control (R)
Number of subjects: 12
Study 33883024 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced PeriOperative Care and Health Protection programme (EPO2CH)
Number of subjects: 0
Study 33883024 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 0
Study 33883024 — intervention group
Group type: EXPERIMENTAL
Intervention: EPO2CH
Number of subjects: 0
Study 33683313 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive treatment (systolic blood pressure goal <120 mm Hg)
Number of subjects: 673
Study 33683313 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (systolic blood pressure goal <140 mm Hg)
Number of subjects: 673
Study 33683313 — intervention group
Group type: COMPARATOR
Intervention: Comparison between intensive and standard treatment
Number of subjects: 673
Study 33683313 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive treatment
Number of subjects: 673
Study 36229224 — intervention group
Group type: COMPARATOR
Intervention: Recombinant human erythropoietin (rhEpo) treatment, 9 IU × kg bw−1, injected three times per week for 4 weeks
Number of subjects: 0
Study 36229224 — intervention group
Group type: COMPARATOR
Intervention: Blood transfusions, 130 ml red blood cells infused
Number of subjects: 0
Study 32612251 — intervention group
Group type: EXPERIMENTAL
Intervention: Engage therapy
Number of subjects: 249
Study 32612251 — intervention group
Group type: COMPARATOR
Intervention: Problem-Solving Therapy (PST)
Number of subjects: 249
Study 32533622 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (early follow-up in a preventive clinic within 1 week)
Number of subjects: 73
Study 32533622 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 73
Study 32533622 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 73
Study 32533622 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 73
Study 34409654 — intervention group
Group type: EXPERIMENTAL
Intervention: Vedolizumab with concomitant immunomodulator use
Number of subjects: 0
Study 34409654 — intervention group
Group type: COMPARATOR
Intervention: Vedolizumab without concomitant immunomodulator use
Number of subjects: 0
Study 33962841 — intervention group
Group type: EXPERIMENTAL
Intervention: NDV-3A vaccine
Number of subjects: 0
Study 33962841 — intervention group
Group type: COMPARATOR
Intervention: Placebo (adjuvant alone)
Number of subjects: 0
Study 35068168 — intervention group
Group type: EXPERIMENTAL
Intervention: Apomorphine sublingual film (APL)
Number of subjects: 0
Study 33813244 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 g of sucrose (S10)
Number of subjects: 59
Study 33813244 — intervention group
Group type: COMPARATOR
Intervention: 15 g of sucrose (S15)
Number of subjects: 59
Study 35997816 — intervention group
Group type: EXPERIMENTAL
Intervention: NAVIGATE (Early Intervention Services)
Number of subjects: 0
Study 35997816 — intervention group
Group type: COMPARATOR
Intervention: CC (Usual Community Care)
Number of subjects: 0
Study 35997816 — intervention group
Group type: EXPERIMENTAL
Intervention: NAVIGATE
Number of subjects: 0
Study 32205557 — intervention group
Group type: EXPERIMENTAL
Intervention: Perineorrhaphy
Number of subjects: 46